12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BNC210: Phase I data

In the first stage of a Phase I trial in healthy volunteers, up to 1,200 mg BNC210 resulted in no significant adverse events. BNC210 achieved blood levels associated with...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >